Trial Profile
A Phase 1 Study to Assess Pharmacokinetics and Pharmacodynamics Following Administration of BAY1093884 in Patients With Severe Hemophilia
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Befovacimab (Primary)
- Indications Haemophilia A; Haemophilia B
- Focus Pharmacokinetics
- Sponsors Bayer
- 25 Feb 2019 Status changed from active, no longer recruiting to completed.
- 11 Feb 2019 Planned End Date changed from 13 Feb 2019 to 20 Feb 2019.
- 21 Dec 2018 Planned End Date changed from 13 Dec 2018 to 13 Feb 2019.